Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics - Wikidata - wikimedia - TriplyDB

Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics

Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics

http://www.wikidata.org/entity/Q35578918

about

Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box Blood-borne phagocytes internalize urate microaggregates and prevent intravascular NETosis by urate crystals Uric acid: the past decade Uric acid as one of the important factors in multifactorial disorders--facts and controversies.Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout Polymorphisms in the presumptive promoter region of the SLC2A9 gene are associated with gout in a Chinese male population.High plasma uric acid concentration: causes and consequences.Orthopaedic case of the month: medial knee pain in a 69-year-old man.Multiple organic anion transporters contribute to net renal excretion of uric acid Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4.New and improved strategies for the treatment of gout TNF-alpha promotes LPA1- and LPA3-mediated recruitment of leukocytes in vivo through CXCR2 ligand chemokines.Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.Hydroxylated chalcones with dual properties: Xanthine oxidase inhibitors and radical scavengers.High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes.Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens.Common genetic variants of the human uromodulin gene regulate transcription and predict plasma uric acid levels SLC2A9--a fructose transporter identified as a novel uric acid transporter.Gout. Novel therapies for treatment of gout and hyperuricemia.Novel drug discovery strategies for gout.Hyperuricemia and gout: new concepts in diagnosis and management.Drug discovery for hyperuricemia.Recent advances in understanding and managing gout Diet-independent relevance of serum uric acid for blood pressure in a representative population sample.Computational Lexical Analysis of the Language Commonly Used to Describe Gout.The development of an effective synthetic route of lesinurad (RDEA594).Self-sufficient control of urate homeostasis in mice by a synthetic circuit.Urate-Lowering Therapy Ameliorates Kidney Function in Type 2 Diabetes Patients With Hyperuricemia.Chronic kidney disease and the risk of incident gout among middle-aged men: a seven-year prospective observational study.Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitor.Enhancement of pharmacological effects of uricosuric agents by concomitant treatment with pyrazinamide in rats.[Crystal-induced arthritis--old but important].

P2860

Q24318894-4C781268-747B-4784-B149-F8C14097FF2C Q30486772-5B7E1E18-BEFF-4FBE-A27B-CA82EFB52C31 Q30830745-4772BBAC-9CDD-4DF1-AD60-A28FE07AEE91 Q33690653-88599158-D04B-4967-B077-C13FF00FE7D9 Q33773142-9C282457-3977-40D9-B294-809C4F17459B Q33973851-D1506874-0657-4ABB-9601-81912AF2A2D6 Q34185594-F9B1941D-ACD9-4A82-B755-852B887B39F4 Q34265901-E3B70FD1-B8A1-438D-9A8C-A8FB20E78A38 Q34434947-430C182A-7597-4B38-8034-7EA8A5C49E93 Q34470733-D07877E5-7CEB-4B0C-8DC3-6E8BB23C34F7 Q34538414-BFD061C8-80D1-4957-AEAD-107F6135BFB5 Q34596040-4D89334F-5D3F-4C3B-BBC0-583B8E5DFA80 Q35026692-B46B3C09-0C2E-4A4C-AB87-D0CCA8B39B45 Q35036338-2C343D40-BB83-4639-990C-6E9FD235B88B Q35192910-6E1534D9-6E0E-49EE-A995-0892CB535683 Q36535526-E1FBF680-A999-4401-B621-8DEE84785C35 Q36662003-BC8936CC-58DA-471A-9248-05A75DA3482E Q36851869-BE398375-4A5A-458A-82B2-98D9B778C7C5 Q36942927-97EC44BB-83FE-4F6F-B7D3-14750C3E0844 Q37209252-64ED1ED5-A5D1-467D-951F-5128C0ADBEB0 Q37350841-84F788CE-9623-4593-B851-9F1C9D9B0D51 Q38066561-355AF265-A370-4536-9FEB-51246CF51204 Q38074338-19CC9B4A-24EE-4999-BC1E-EDC9D4023F15 Q38089866-FF7E8CD5-0AD2-4394-91AD-68322F971604 Q39207801-F843B69A-2CC7-4C22-834F-14A64D87344E Q40140234-7116583E-4E91-4488-84ED-5544CDE15536 Q40491609-4768357F-CEDB-4659-9F30-B832F0C06A64 Q42766937-93CD76BC-FB41-45C7-BFB4-498C2FA509AD Q43115408-750A736F-2D46-4432-BFDE-F68284643C0A Q45158703-CF943BE4-25E5-40B4-A42A-2BDA4256C996 Q46070363-ECD3314F-4DED-43E6-8A3D-7552DC3626DC Q47896324-21E6F654-88B2-4E92-A653-CBC0A7D2BBBA Q48172752-99F85EF6-4563-4AFB-B329-CDD6F9F2FBDE Q50691939-8D9BA00F-D259-4514-B371-4021F41869B2

P2860

Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics

http://www.wikidata.org/entity/Q35578918

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Recent developments in our und ...... antihyperuricemic therapeutics

@ast

Recent developments in our und ...... antihyperuricemic therapeutics

@en

type

label

Recent developments in our und ...... antihyperuricemic therapeutics

@ast

Recent developments in our und ...... antihyperuricemic therapeutics

@en

prefLabel

Recent developments in our und ...... antihyperuricemic therapeutics

@ast

Recent developments in our und ...... antihyperuricemic therapeutics

@en

P1433

Q35578918-A898CCC6-B69D-42DD-89C5-4603AD13C508

P1476

Q35578918-8EC28AC5-8862-4907-B03D-9562D16C6FA7

P2093

Q35578918-7559C2E9-041B-4084-9C15-A411F8171A76

Q35578918-976F01BD-7BF7-4FBD-A3A0-B4A7B82EA003

Q35578918-AAA99BA7-2F5D-459D-A77B-834478014149

P2860

Q35578918-00FA8BB2-9FFE-4197-A62F-B0A637A29850

Q35578918-06D27ECB-73A0-45D7-8B91-8C760FDA327A

Q35578918-0A565258-55A6-4089-8DFF-54320173DD8F

Q35578918-0ACA2AD0-07FF-43CC-8874-B8B3276FEE9E

Q35578918-0C180440-53F5-4614-9B5D-913E4253F2C2

Q35578918-0E720626-6B76-4AA1-AAF1-F3DB1E62B231

Q35578918-0FC585E0-F70A-446E-BDAC-D8545E25B06F

Q35578918-10E2931A-53B3-4AD2-AE89-BA21C1DF00FC

Q35578918-1DCDFA77-BC67-40AE-90C2-B37BE9552AC8

Q35578918-241D3309-136C-4EFF-8318-F3E534119FB0

P2888

Q35578918-FEAC528F-4669-40C8-9B5D-F6C9CF6FCBE7

P304

Q35578918-6A1F021F-99CF-4C4C-98AB-E3DCE4B1EE10

P31

Q35578918-1D8860A7-4045-40BD-A489-94DEC9BAD81A

Q35578918-8DBBF24C-8B0D-4668-BB25-1C8F536982FA

P356

Q35578918-2067C973-E64B-4803-B130-E7D6B1ADA9A3

P478

Q35578918-E5A6FCFF-A156-4CC9-A534-68C912B6233A

P577

Q35578918-584C2F86-1E70-4C92-97CB-B7CFC8D57125

P5875

Q35578918-D8764011-F2A3-4573-8A17-936E9AE589EA

P6179

Q35578918-65BE3F2C-DF5A-492D-A625-A5467D09EF6E

P698

Q35578918-29E239A8-19F9-4856-85DA-055A10EBD335

P921

Q35578918-2A1DE3EB-204E-43F8-A513-D84F0B4336AF

Q35578918-C0293C69-4C23-4CB4-AF44-EB4D556F6353

P932

Q35578918-B8ADC2A9-FEE7-439C-82B0-4ABED7A9F65D

P356

P1433

Arthritis Research and Therapy

P1476

Recent developments in our und ...... antihyperuricemic therapeutics

@en

P2093

David A Bushinsky

http://www.w3.org/2001/XMLSchema#string

Michael A Becker

http://www.w3.org/2001/XMLSchema#string

Robert Terkeltaub

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular identification of a renal urate anion exchanger that regulates blood urate levels

Molecular physiology of urate transport

The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus

Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

Microdialytical monitoring of uric and ascorbic acids in the brains of patients after severe brain injury and during neurovascular surgery

Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter

Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.

P2888

P304

S4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR1909

http://www.w3.org/2001/XMLSchema#string

P478

8 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6965021

http://www.w3.org/2001/XMLSchema#string

P6179

1039896024

http://www.w3.org/2001/XMLSchema#string

P698

16820043

http://www.w3.org/2001/XMLSchema#string

P921

genitourinary system

P932

3226109

http://www.w3.org/2001/XMLSchema#string